logo

For the Inventor, By the Inventor

Shrewsbury, MA, United States of America

Örn Almarsson

This inventor holds 16 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignees: Transform Pharmaceuticals, Inc., Alkermes Pharma Ireland Limited, Mcneil-Ppc, Inc.. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Örn Almarsson. Retrieved from https://idiyas.com/inventor/örn-almarsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 43.8

 

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 225(Granted Patents)


Location History:

  • Shewsbury, MA (US) (2005)
  • Shrewsbury, MA (US) (2006 - 2019)

Company Filing History:

goldMedal5 out of 28 
 
Transform Pharmaceuticals, Inc.
 patents
silverMedal4 out of 164 
 
Alkermes Pharma Ireland Limited
 patents
bronzeMedal4 out of 798 
 
Mcneil-Ppc, Inc.
 patents
4. 3 out of 247 
 
Modernatx, Inc.
 patents
5. 2 out of 1,990 
 
University of South Florida
 patents
6. 1 out of 3,536 
 
University of Michigan
 patents
where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 12383508 - High-purity peg lipids and uses thereof (2025-08-12),
2. 10258698 - Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions (2019-04-16),
3. 9925277 - Polynucleotide compositions containing amino acids (2018-03-27),
4. 9670200 - Quaternary ammonium salt prodrugs (2017-06-06),
5. 9107911 - Prodrugs of heteraromatic compounds (2015-08-18),
6. 8686009 - Prodrugs of NH-acidic compounds (2014-04-01),
7. 8592427 - Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives (2013-11-26),
8. 8492423 - Pharmaceutical propylene glycol solvate compositions (2013-07-23),
9. 8436029 - Pharmaceutical forms, and methods of making and using the same (2013-05-07),
10. 8362062 - Pharmaceutical compositions with improved dissolution (2013-01-29),
11. 8183290 - Pharmaceutically acceptable propylene glycol solvate of naproxen (2012-05-22),
12. 7927613 - Pharmaceutical co-crystal compositions (2011-04-19),
13. 7790905 - Pharmaceutical propylene glycol solvate compositions (2010-09-07),
14. 7671093 - Mixed co-crystals and pharmaceutical compositions comprising the same (2010-03-02),
15. 7061605 - Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions (2006-06-13),

Title: Örn Almarsson: Innovator in Lipid Nanoparticle Formulations

Introduction

Örn Almarsson is a prominent inventor based in Shrewsbury, MA (US), known for his significant contributions to the field of lipid nanoparticle formulations. With a total of 16 patents to his name, Almarsson has made remarkable advancements in the development of high-purity PEG lipids and their applications in therapeutic delivery systems.

Latest Patents

Almarsson's latest patents include groundbreaking work on high-purity PEG lipids and their uses. The first patent highlights the discovery that these lipids exhibit superior physical and biological properties, particularly in lipid nanoparticle (LNP) formulations. This innovation provides PEG lipids at a recommended purity for use in various formulations, including LNPs that deliver therapeutic agents effectively. Another notable patent focuses on the formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions. This patent outlines compositions that include modified nucleic acid molecules capable of encoding proteins or their precursors, enhancing the potential for therapeutic applications.

Career Highlights

Throughout his career, Örn Almarsson has worked with notable companies such as Transform Pharmaceuticals, Inc. and Alkermes Pharma Ireland Limited. His work in these organizations has contributed to the advancement of pharmaceutical technologies and innovative drug delivery systems.

Collaborations

Almarsson has collaborated with esteemed colleagues, including Julius F Remenar and Mark Tawa. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of pharmaceutical research.

Conclusion

Örn Almarsson's contributions to the field of lipid nanoparticle formulations and his extensive patent portfolio underscore his role as a leading inventor. His work continues to influence the development of advanced therapeutic delivery systems, showcasing the importance of innovation in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…